1. Home
  2. CDT vs IDAI Comparison

CDT vs IDAI Comparison

Compare CDT & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • IDAI
  • Stock Information
  • Founded
  • CDT 2019
  • IDAI 2016
  • Country
  • CDT United States
  • IDAI United States
  • Employees
  • CDT N/A
  • IDAI N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • IDAI Computer Software: Prepackaged Software
  • Sector
  • CDT Health Care
  • IDAI Technology
  • Exchange
  • CDT Nasdaq
  • IDAI Nasdaq
  • Market Cap
  • CDT 5.3M
  • IDAI 5.5M
  • IPO Year
  • CDT N/A
  • IDAI N/A
  • Fundamental
  • Price
  • CDT $0.40
  • IDAI $2.33
  • Analyst Decision
  • CDT
  • IDAI
  • Analyst Count
  • CDT 0
  • IDAI 0
  • Target Price
  • CDT N/A
  • IDAI N/A
  • AVG Volume (30 Days)
  • CDT 3.1M
  • IDAI 54.1K
  • Earning Date
  • CDT 05-20-2025
  • IDAI 05-20-2025
  • Dividend Yield
  • CDT N/A
  • IDAI N/A
  • EPS Growth
  • CDT N/A
  • IDAI N/A
  • EPS
  • CDT N/A
  • IDAI N/A
  • Revenue
  • CDT N/A
  • IDAI $3,082,348.00
  • Revenue This Year
  • CDT N/A
  • IDAI $65.46
  • Revenue Next Year
  • CDT N/A
  • IDAI $12.00
  • P/E Ratio
  • CDT N/A
  • IDAI N/A
  • Revenue Growth
  • CDT N/A
  • IDAI N/A
  • 52 Week Low
  • CDT $0.51
  • IDAI $0.15
  • 52 Week High
  • CDT $350.00
  • IDAI $8.96
  • Technical
  • Relative Strength Index (RSI)
  • CDT 31.06
  • IDAI 66.26
  • Support Level
  • CDT $0.37
  • IDAI $1.94
  • Resistance Level
  • CDT $0.57
  • IDAI $2.13
  • Average True Range (ATR)
  • CDT 0.05
  • IDAI 0.16
  • MACD
  • CDT 0.01
  • IDAI 0.06
  • Stochastic Oscillator
  • CDT 13.89
  • IDAI 94.90

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility.

Share on Social Networks: